History

Setmelanotide was invented at Ipsen (first coded BIM-22493, later RM-493 / IRC-022493). In March 2010 Ipsen licensed the program worldwide to Rhythm Pharmaceuticals, which renamed it RM-493 and ran the clinical development. First-in-human pharmacology was published in 2015. The FDA granted first approval in November 2020 for POMC/PCSK1 and LEPR deficiency, and the EMA followed in July 2021. The label has since expanded to Bardet-Biedl syndrome (2022), down to age 2 (2024), and to acquired hypothalamic obesity (March 2026).

Setmelanotide, sold as Imcivree, is a prescription peptide for a handful of rare, well-defined forms of severe obesity. Within those narrow conditions the evidence is genuinely strong. Outside them — for general weight loss, fat loss, or “metabolism” boosting in people without these disorders — there is no credible evidence at all. Both halves of that statement matter.

What it is

Setmelanotide is a synthetic cyclic octapeptide (eight amino acids), built as an analogue of the body’s natural appetite hormone, alpha-melanocyte-stimulating hormone (alpha-MSH). It is cyclized by a disulfide bridge between its two cysteines and keeps alpha-MSH’s essential His-Phe-Arg-Trp core, using a D-phenylalanine for stability and potency. Its molecular formula is C49H68N18O9S2 (about 1117 Da), and the registered FDA label name is acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidinyl-D-phenylalanyl-L-arginyl-L-tryptophanyl-L-cysteinamide, cyclic (2-to-8)-disulfide, acetate.

Mechanistically, it is a selective agonist at the melanocortin-4 receptor (MC4R), a receptor in the hypothalamus that sits at the center of the leptin-to-POMC-to-MC4R satiety pathway. In the rare diseases it treats, that pathway is broken somewhere upstream. Setmelanotide re-activates MC4R downstream of the defect, which reduces hunger and food intake and modestly raises energy expenditure. It is roughly 20-fold more active at MC4R than at the related MC3R and MC1R receptors; the residual MC1R activity is why skin darkening is a side effect. The active, drug-bound receptor structure has been solved by cryo-electron microscopy (PDB 7PIU). It is given as a subcutaneous injection.

The claims

The legitimate, approved claim is narrow: chronic weight management in specific rare genetic or acquired forms of severe obesity. It is an orphan drug, not a treatment for common obesity, diabetes, or general weight management. It is also being investigated in other MC4R-pathway gene variants and in Prader-Willi syndrome, where the manufacturer reported an early, exploratory efficacy signal in late 2025 — a press-release-stage result, not proof.

The framing it is most likely to be encountered in online and gray-market settings is different: appetite control, fat loss, body recomposition, or “metabolism” boosting in otherwise healthy people. Those uses have no supporting evidence and are not what the drug was studied or approved for.

The evidence

The human data fall into a clear pattern: strong for each approved indication, absent for everything else.

Early pharmacology came from Chen and colleagues (2015), a randomized, double-blind crossover study using a 72-hour continuous subcutaneous infusion in 12 adults with obesity. Resting energy expenditure rose about 6.4% (roughly 111 kcal/day) versus placebo, with a shift toward fat oxidation and no adverse heart-rate or blood-pressure signal. This was mechanistic proof-of-concept, very short term.

The pivotal trials behind the 2020 approval were reported by Clement and colleagues (2020): two single-arm, open-label phase 3 trials in POMC deficiency (10 patients) and LEPR deficiency (11 patients), including a blinded placebo-controlled withdrawal sequence within the open-label design. At about one year, 8 of 10 POMC patients and 5 of 11 LEPR patients achieved at least 10% weight loss, with mean hunger scores falling 27% and 44% respectively. These were striking results, but the trials were tiny, single-arm, open-label, and company-funded.

For Bardet-Biedl syndrome (the 2022 expansion), Haqq and colleagues (2022) ran a multicentre, randomized, double-blind, placebo-controlled trial — 38 patients total, 19 per arm, with a 14-week core followed by open-label treatment. Among BBS patients aged 12 and older, 32.3% reached at least 10% weight loss at 52 weeks (p=0.0006). Results were inconclusive in the small group of Alstrom patients, who were dropped from the indication.

The VENTURE trial (Argente and colleagues, 2024) supported lowering the minimum age to 2: a one-year, open-label study in 12 children aged 2 to 5 with POMC/LEPR deficiency or BBS, with a mean BMI reduction of about 18% at one year.

Most recently, the TRANSCEND trial supported the March 2026 approval for acquired hypothalamic obesity — a randomized, placebo-controlled, 52-week study in 142 patients (94 on drug, 48 on placebo). BMI fell 15.8% on setmelanotide versus a 2.6% rise on placebo, a placebo-adjusted difference of 18.4% (p<0.0001). As of this writing those figures come from the manufacturer’s release; the peer-reviewed publication should be checked before treating them as final.

What is missing is just as important. There are no trials in common (polygenic) obesity or in people without a defined pathway defect. The monogenic pivotal trials are very small and single-arm. Long-term cardiometabolic and safety data are limited for a drug meant for chronic use. And there is a pervasive conflict of interest: every pivotal trial was funded by the manufacturer, Rhythm Pharmaceuticals, with company-affiliated authors, and independent replication is scarce given how rare these diseases are. None of this undercuts the approvals — but it is the honest context.

Safety and side effects

The most distinctive side effect is skin hyperpigmentation, driven by the drug’s residual MC1R activity. In the BBS trial, hyperpigmentation occurred in roughly 61% of patients and injection-site reactions in about half. Other common effects include nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

The DailyMed label carries several specific warnings. Because the drug stimulates melanocytes, it can darken pre-existing moles and prompt new ones, so a full-body skin exam is required before starting and periodically during treatment; no treatment-related melanoma has been reported in trials, but this is a monitoring-driven concern. The label also flags disturbance in sexual arousal (including spontaneous erections lasting over four hours, which warrant urgent care), depression and suicidal ideation (monitor and discontinue if persistent), serious hypersensitivity including anaphylaxis, and the presence of benzyl alcohol as a preservative (a neonatal caution). The drug has an elimination half-life of about 11 hours, with roughly 39% excreted unchanged in urine within 24 hours.

The reassuring counterpoint is that no serious treatment-related adverse events emerged in the small monogenic pivotal trials, and the 2015 infusion study showed no adverse cardiovascular signal. The caveat is that these safety datasets are small and short for a medicine intended for long-term use. This is not medical advice; setmelanotide is a prescription drug that requires monitoring.

Legal and regulatory status

Setmelanotide is an approved prescription orphan drug, not a supplement or research chemical. The FDA first approved it in November 2020 for POMC/PCSK1 and LEPR deficiency in patients aged 6 and older, then expanded it to Bardet-Biedl syndrome (2022), lowered the minimum age to 2 (December 2024, on the VENTURE data), and approved it for acquired hypothalamic obesity (19 March 2026, on TRANSCEND). The EMA authorized it on 16 July 2021 for genetically confirmed BBS and biallelic POMC (including PCSK1) or LEPR deficiency, and the EU label now also reflects acquired hypothalamic obesity. Health Canada has also reviewed it.

For athletes, the picture requires care. Setmelanotide is not listed by name on the WADA Prohibited List, and we could not confirm that melanocortin agonists form a named category. But as a peptide acting on a hormone receptor, it plausibly falls within the scope of S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), and S0 (Non-Approved Substances) would capture any use outside an approved therapeutic context. The practical takeaway is to treat it as prohibited and high-risk without a Therapeutic Use Exemption, and to check the current list — this is reasoned inference from the substance class, not a verbatim listing.

As an injectable peptide, setmelanotide also turns up on the research-chemical gray market, where products are unapproved and unregulated for identity, purity, and sterility. Sold or used for general weight loss, it is off-label, unstudied, and — if marketed for human use that way — a misbranded, unapproved drug.

Bottom line

Setmelanotide is a real success story in a very small place. For the rare genetic and acquired forms of obesity it was tested and approved for, the evidence is strong: dedicated phase 3 trials, large effects, and clear regulatory approval, tempered by small single-arm pivotal studies and heavy manufacturer involvement. For the way most people might encounter it — general weight loss in someone without one of these conditions — there is no credible evidence of benefit and a side-effect profile that is not trivial. The honest read is to keep those two worlds separate.

Evidence grade: Strong human (within approved rare-disease indications); no credible evidence for general or gray-market weight-loss use.

Setmelanotide (Imcivree): Strong Evidence in Rare Obesity, None Beyond It